PHGDH-amplified cells are dependent on expression of catalytically active enzyme to proliferate [3], and high PHGDH expression is associated with negative clinical outcomes in breast cancer [1, 2, 4], glioma [5], cervical cancer [6], lung cancer [7], and colon cancer [8]. This evidence concerns the gene PHGDH and central nervous system cancer.